List of Figures
Figure 1: Genetic Disorders, CF Testing Algorithm 18
Figure 2: Epidemiology Patterns for Cystic Fibrosis, 2016–2023 27
Figure 3: Epidemiology Patterns for Duchenne Muscular Dystrophy, 2016–2023 28
Figure 4: Epidemiology Patterns for Lysosomal Storage Disease, 2016–2023 29
Figure 5: Epidemiology Patterns for Paroxysmal Nocturnal Hemoglobinuria, 2016–2023 29
Figure 6: Genetic Disorders, Progression of CF 34
Figure 7: Genetic Disorders, Schema for Initiation of Glucocorticoid Treatment in Duchenne Muscular Dystrophy, 2017 40
Figure 8: Genetic Disorders, Global, Key Marketed Products and Approved Indications, 2017 44
Figure 9: Genetic Disorders Market, Global, Annual Revenue for Soliris ($bn), 2007–2023 46
Figure 10: Genetic Disorders Market, Global, Annual Revenue for Orkambi ($bn), 2015–2023 47
Figure 11: Genetic Disorders Market, Global, Annual Revenue for Cerezyme ($bn), 2006–2023 49
Figure 12: Genetic Disorders Market, Global, Annual Revenue for Myozyme/Lumizyme ($bn), 2006–2023 51
Figure 13: Genetic Disorders Market, Global, Annual Revenue for Fabrazyme ($bn), 2006–2023 53
Figure 14: Genetic Disorders Market, Global, Annual Revenue for Pulmozyme ($bn), 2006–2023 54
Figure 15: Genetic Disorders Market, Global, Annual Revenue for Kalydeco ($bn), 2012–2023 56
Figure 16: Genetic Disorders Market, Global, Annual Revenue for Elaprase ($bn), 2006–2023 58
Figure 17: Genetic Disorders Market, Global, Annual Revenue for Vimizim ($bn), 2014–2023 59
Figure 18: Genetic Disorders Market, Global, Annual Revenue for Cerdelga ($bn), 2014–2023 61
Figure 19: Genetic Disorders Market, Global, Annual Revenue for Exondys 51 ($bn), 2016–2023 62
Figure 20: Genetic Disorders Market, Global, Overall Pharmaceutical Industry Pipeline by Genetic Disorders, 2017 63
Figure 21: Genetic Disorders Market, Global, Genetic Disorders Pipeline by Stage of Development and Molecule Type, 2017 64
Figure 22: Genetic Disorders Market, Global, Pipeline for Key Genetic Disorders Indications by Stage of Development, 2017 65
Figure 23: Genetic Disorders Market, Global, Pipeline for Key Genetic Disorders Indications by Molecule Type, 2017 66
Figure 24: Genetic Disorders Market, Global, Genetic Disorders Pipeline by Molecular Target, 2017 67
Figure 25: Genetic Disorders Market, Global, Pipeline for Key Genetic Disorders Indications by Molecular Target, 2017 68
Figure 26: Genetic Disorders Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006–2017 69
Figure 27: Genetic Disorders Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006–2017 70
Figure 28: Genetic Disorders Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006–2017 71
Figure 29: Genetic Disorders Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006–2017 72
Figure 30: Genetic Disorders Market, Global, Clinical Trial Duration by Stage of Development (months), 2006–2017 73
Figure 31: Genetic Disorders Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006–2017 74
Figure 32: Genetic Disorders Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006–2017 75
Figure 33: Genetic Disorders Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006–2017 76
Figure 34: Genetic Disorders Market, Global, Clinical Trial Size by Stage of Development (participants), 2006–2017 77
Figure 35: Genetic Disorders Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006–2017 78
Figure 36: Genetic Disorders Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006–2017 79
Figure 37: Genetic Disorders Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006–2017 80
Figure 38: Genetic Disorders Market, Global, Clinical Program Size by Stage of Development (participants), 2006–2017 81
Figure 39: Genetic Disorders Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006–2017 82
Figure 40: Genetic Disorders Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006–2017 83
Figure 41: Genetic Disorders Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006–2017 84
Figure 42: Genetic Disorders Market, Global, Revenue Forecast for Epidiolex ($m), 2018–2023 86
Figure 43: Genetic Disorders Market, Global, Revenue Forecast for ALXN-1210 (ravulizumab) ($m), 2019–2023 87
Figure 44: Genetic Disorders Market, Global, Revenue Forecast for Lanadelumab ($m), 2018–2023 88
Figure 45: Genetic Disorders Market, Global, Revenue Forecast for Burosumab ($m), 2018–2023 90
Figure 46: Genetic Disorders Market, Global, Revenue Forecast for GBT440 (voxelotor) ($m), 2020–2023 91
Figure 47: Genetic Disorders Market, Global, Revenue Forecast for Ivacaftor and Tezacaftor ($m), 2018–2023 92
Figure 48: Genetic Disorders Market, Global, Market Size ($bn), 2016–2023 93
Figure 49: Genetic Disorders Market, Global, Annual Revenue Forecast for Premium and Generic Products ($bn), 2016–2023 95
Figure 50: Genetic Disorders Market, Global, Annual Revenue Forecast for Immune/Inflammatory Mediators ($bn), 2016–2023 97
Figure 51: Genetic Disorders Market, Global, Annual Revenue Forecast for Enzyme Replacement/Modifying Therapies ($bn), 2016–2023 98
Figure 52: Genetic Disorders Market, Global, Annual Revenue Forecast for Ion Channel Modulators ($bn), 2016–2023 99
Figure 53: Genetic Disorders Market, Global, Annual Revenue Forecast for G Protein-Coupled Receptor Modulators ($bn), 2016–2023 100
Figure 54: Genetic Disorders Market, Global, Annual Revenue Forecast for Metabolic Enzyme Mediators ($bn), 2016–2023 101
Figure 55: Genetic Disorders Therapeutics Market, Global, Company Analysis Matrix, 2016–2023 102
Figure 56: Genetic Disorders Market, Global, Cluster by Growth and Market Share, 2016–2023 103
Figure 57: Genetic Disorders Market, Global, Forecast Market Share by Company (%), 2016–2023 106
Figure 58: Genetic Disorders Market, Global, Companies by Compound Annual Growth Rate (%), 2016–2023 107
Figure 59: Genetic Disorders Market, Global, Revenues by Product Type, 2016–2023 108
Figure 60: Genetic Disorders Market, Global, Alexion Annual Revenue Forecast ($bn), 2016–2023 109
Figure 61: Genetic Disorders Market, Global, Sanofi Annual Revenue Forecast ($bn), 2016–2023 110
Figure 62: Genetic Disorders Market, Global, Vertex Annual Revenue Forecast ($bn), 2016–2023 111
Figure 63: Genetic Disorders Market, Global, Shire Annual Revenue Forecast ($bn), 2016–2023 112
Figure 64: Genetic Disorders Market, Global, Amgen Annual Revenue Forecast ($bn), 2016–2023 113
Figure 65: Genetic Disorders Market, Global, GW Pharmaceuticals Annual Revenue Forecast ($bn), 2016–2023 114
Figure 66: Genetic Disorders Market, Global, Pfizer Annual Revenue Forecast ($bn), 2016–2023 115
Figure 67: Genetic Disorders Market, Global, BioMarin Annual Revenue Forecast ($bn), 2016–2023 116
Figure 68: Genetic Disorders Market, Global, Sarepta Annual Revenue Forecast ($bn), 2016–2023 117
Figure 69: Genetic Disorders Market, Global, Companies by Type, 2017 118
Figure 70: Genetic Disorders Market, Global, Pipeline, High-Activity and Late-Stage Developers by Level of Genetic Disorders Specialization, 2017 119
Figure 71: Genetic Disorders Market, Global, Proportion of Total Company Revenue Attributed to Genetic Disorders, 2016–2023 120
Figure 72: Genetic Disorders Market, Global, Licensing Deals by Region, Year and Value, 2006–2017 122
Figure 73: Genetic Disorders Market, Global, Licensing Deals by Indication, 2006–2017 123
Figure 74: Genetic Disorders Market, Global, Licensing Deals by Stage of Development and Value, 2006–2016 124
Figure 75: Genetic Disorders Market, Global, Licensing Deals by Molecule Type and Molecular Target, 2006–2017 125
Figure 76: Genetic Disorders Market, Global, Co-development Deals by Region, Year and Value, 2006–2017 130
Figure 77: Genetic Disorders Market, Global, Co-development Deals by Indication, 2006–2017 131
Figure 78: Genetic Disorders Market, Global, Co-development Deals by Stage of Development and Value, 2006–2017 132
Figure 79: Genetic Disorders Market, Global, Co-development Deals by Molecule Type and Molecular Target, 2006–2017 133
Figure 80: Genetic Disorders, Global, Table of all Clinical Stage Pipeline Products, 2017, Part 1 147
Figure 81: Genetic Disorders, Global, Table of all Clinical Stage Pipeline Products, 2017, Part 2 148
Figure 82: Genetic Disorders, Global, Table of all Clinical Stage Pipeline Products, 2017, Part 3 149
Figure 83: Genetic Disorders, Global, Table of all Clinical Stage Pipeline Products, 2017, Part 4 150
Figure 84: Genetic Disorders, Global, Table of all Clinical Stage Pipeline Products, 2017, Part 5 151
Figure 85: Genetic Disorders, Global, Table of all Clinical Stage Pipeline Products, 2017, Part 6 152
Figure 86: Genetic Disorders, Global, Table of all Clinical Stage Pipeline Products, 2017, Part 7 153
Figure 87: Genetic Disorders, Global, Table of all Clinical Stage Pipeline Products, 2017, Part 8 154
Figure 88: Genetic Disorders, Global, Table of all Clinical Stage Pipeline Products, 2017, Part 9 155
Figure 89: Genetic Disorders, Global, Table of all Clinical Stage Pipeline Products, 2017, Part 10 156